Get started
Author

Swetlana Ladigan

Observed names: Ladigan, Swetlana, S. Ladigan, Swetlana Ladigan (8144127)
ORCID: 0000-0003-1923-4096
Observed ORCID: 0000-0003-1923-4096
OpenAlex ID: A5110698271
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer
2019 · Jörn Weisner, Ina Landel, et al. · Cancer Research · 91
Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
2020 · Susanne Klein-Scory, Ingo Wahner, et al. · Frontiers in Oncology · 52
PDF
Characterization of a dual BET / HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma
2020 · Xin Zhang, Tim Zegar, et al. · International Journal of Cancer · 50
PDF
Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
2019 · Thomas Mika, Katharina Strate, et al. · Frontiers in Medicine · 27
PDF
Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma
2019 · Thomas Mika, Swetlana Ladigan, et al. · Haematologica · 18
PDF
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Deepak Vangala, Swetlana Ladigan, et al. · Genome Medicine · 16
PDF
Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription
2023 · Donald P. Cameron, Jan Grosser, et al. · Science Advances · 15
Monocytes-neutrophils-ratio as predictive marker for failure of first induction therapy in AML
2019 · Thomas Mika, Swetlana Ladigan, et al. · Blood Cells Molecules and Diseases · 12
Acute myeloid leukemia with central diabetes insipidus
2019 · Swetlana Ladigan, Thomas Mika, et al. · Blood Cells Molecules and Diseases · 11
Value of EGD for gastric cancer surveillance in patients with hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome (LS).
2018 · Swetlana Ladigan, Deepak B. Vangala, et al. · Journal of Clinical Oncology · 4
Clinical characteristics and EGD surveillance in Lynch-syndrome patients with small bowel/duodenal carcinomas.
2018 · Deepak B. Vangala, Christian Pox, et al. · Journal of Clinical Oncology · 3
Additional file 6 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Vangala, Deepak, Ladigan, Swetlana, et al. · Figshare
Additional file 1 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Vangala, Deepak, Ladigan, Swetlana, et al. · Figshare
Additional file 3 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Vangala, Deepak, Ladigan, Swetlana, et al. · Figshare
Additional file 7 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Vangala, Deepak, Ladigan, Swetlana, et al. · Figshare
Additional file 5 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Vangala, Deepak, Ladigan, Swetlana, et al. · Figshare
Additional file 4 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Vangala, Deepak, Ladigan, Swetlana, et al. · Figshare
Abstract 1873: Drivers of secondary resistance to anti-EGFR therapy in metastatic colorectal cancer
2020 · Soha Hussein Noseir, Stephan Hahn, et al. · Cancer Research
SO-33 Clonal selection of RAS mutant metastatic colorectal cancer into RAS wild-type during first-line therapy
2020 · S. Klein-Scory, I. Wahner, et al. · Annals of Oncology
PDF
Verbundprojekt „Familiärer Darmkrebs“
2017 · Swetlana Ladigan, Deepak Vangala, et al. · Forum
Works count: 30
Citation count: 299
H-index: 9
I10-index: 9
Year
Topic
Type